Medpace’s (MEDP) Market Perform Rating Reiterated at William Blair

William Blair reissued their market perform rating on shares of Medpace (NASDAQ:MEDP) in a report published on Tuesday morning, Marketbeat Ratings reports. William Blair also issued estimates for Medpace’s Q3 2025 earnings at $2.95 EPS, Q4 2025 earnings at $2.80 EPS, Q1 2026 earnings at $3.17 EPS and Q2 2026 earnings at $3.12 EPS.

MEDP has been the topic of several other reports. Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. TD Cowen cut shares of Medpace from a “buy” rating to a “hold” rating and cut their price target for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective for the company. Truist Financial reduced their target price on Medpace from $347.00 to $333.00 and set a “hold” rating for the company in a report on Thursday, April 10th. Finally, Leerink Partnrs upgraded Medpace to a “hold” rating in a report on Monday, March 24th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $349.30.

Medpace Price Performance

Shares of Medpace stock opened at $302.88 on Tuesday. The business has a 50-day simple moving average of $314.64 and a 200 day simple moving average of $332.04. The firm has a market capitalization of $9.16 billion, a price-to-earnings ratio of 23.98, a PEG ratio of 3.81 and a beta of 1.46. Medpace has a one year low of $250.05 and a one year high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million for the quarter, compared to analysts’ expectations of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period last year, the business earned $3.20 EPS. On average, sell-side analysts expect that Medpace will post 12.29 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MEDP. Pallas Capital Advisors LLC boosted its holdings in shares of Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after acquiring an additional 2,101 shares during the period. Barclays PLC boosted its stake in Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC grew its holdings in Medpace by 20.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after buying an additional 844 shares in the last quarter. SYM FINANCIAL Corp bought a new stake in shares of Medpace during the fourth quarter valued at about $320,000. Finally, Tokio Marine Asset Management Co. Ltd. purchased a new stake in shares of Medpace in the fourth quarter worth about $9,335,000. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.